Clinical Trials


Clinical Trials & Registries

Registry Observing trial:

  1. Celgene

AZA-MDS-006: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry


  1. Miraca

MLSREG-0001-V1: A Registry of Hematopoietic Diseases for Evaluation of Correlation with Clinical Outcomes


  1. Guardant

03-001: The NILE Trial: Noninvasive vs. Invasive Lung genotyping Evaluation (The NILE Trial)


Intervention trials:

  1. Seattle Genetics:

SGN19A-004 : An open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) in combination with RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) compared with RCHOP alone as frontline therapy in patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) Grade 3b


  1. Oncotherapeutics

X10641: A phase 2 study of Ixazomib as a replacement for Bortezomib or Carfilzomib for multiple (MM) patients recently relapsed or refractory to their last combination regimen containing either Bortezomib or Carfilzomib


  1. Celgene

CC-5013-NHL-008: MAGNIFY : A Phase 3b Randomized Study Of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed By Lenalidomide Single-Agent Maintenance versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma


  1. Centus – Parexel

AVANA trial: FKB238-002: A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients with Advanced/Recurrent Non-Squamous Non-Small Cell Lung Cancer in Combination of Paclitaxel and Carboplatin


  1. TG Therapeutics
  • UTX-TGR-304: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)


  • UTX-TGR-205: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma


  1. United Therapeutics Corporation

DIV-SCLC-301::A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer